Curated News
By: NewsRamp Editorial Staff
July 08, 2026
NanoViricides Gets Outperform Rating; CEO Discusses Broad-Spectrum Antiviral NV-387
TLDR
- NanoViricides received an Outperform rating and $6 price target from Noble Capital Markets, signaling potential upside.
- NanoViricides' platform uses nanoviricide technology to target viruses; NV-387 is a broad-spectrum candidate for multiple diseases.
- NanoViricides aims to combat resurgent infectious diseases like measles and Ebola, potentially improving global health.
- NanoViricides' NV-387 has FDA Orphan Drug Designation and a Rare Pediatric Disease Designation filing for measles.
Impact - Why it Matters
This news matters because NanoViricides' broad-spectrum antiviral candidate NV-387 could address multiple viral threats simultaneously, including COVID-19, RSV, influenza, and emerging diseases like mpox and measles. With the resurgence of infectious diseases, a single drug effective against diverse viruses would revolutionize pandemic preparedness and treatment options. The analyst's positive rating and price target signal growing investor confidence, while the CEO's discussion of regulatory progress suggests the company is advancing toward clinical trials. For investors and public health advocates, this development highlights a potential game-changer in antiviral therapy.
Summary
NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, has received an “Outperform” rating and a $6.00 price target from analyst Robert LeBoyer of Noble Capital Markets. The coverage highlights the company’s lead broad-spectrum antiviral candidate NV-387, which targets multiple viral diseases including RSV, COVID-19, Influenza, and even Measles. NanoViricides provided publicly available information and technical clarifications, but the analyst independently developed all financial projections.
In parallel, President and Executive Chairman Anil R. Diwan participated in a “Fireside Chat” with StockInvestor Daily’s IPO-Edge program. He discussed the company’s antiviral technology platform, the potential of NV-387 against viral variants, and regulatory milestones such as FDA Orphan Drug Designation and a Rare Pediatric Disease Designation filing for measles. Diwan also highlighted the resurgence of infectious diseases like measles, mpox, and Ebola, underscoring the urgent need for broad-spectrum antivirals.
NanoViricides’ platform leverages TheraCour nanomedicine technology, with a pipeline that includes NV-CoV-2 (API NV-387) for COVID-19 and NV-CoV-2-R, which encapsulates remdesivir. The company is also developing treatments for herpes, influenza, HIV, and Ebola. The recent analyst coverage and executive commentary reinforce the company’s strategic focus on advancing NV-387 into Phase II human clinical trials. For more details, visit the full press release at https://ibn.fm/7XBbY.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, NanoViricides Gets Outperform Rating; CEO Discusses Broad-Spectrum Antiviral NV-387
